ATLANTA—Rheumatic diseases have been the subject of a range of public health campaigns and reports over the past decade, but improving their visibility remains a work in progress, a Centers for Disease Control and Prevention (CDC) expert said at the 2019 ACR/ARP Annual Meeting. A growing attention to pain and the opioid crisis may help…
FDA Update: New Drug Approvals, New & Expanded Indications, & More
ATLANTA—New drug approvals, new and expanded drug indications, and important safety and other updates relevant for rheumatologists were presented by three physicians from the U.S. Food & Drug Administration (FDA) on Nov. 11 at the 2019 ACR/ARP Annual Meeting. New JAK Inhibitor Approved for RA On Aug. 16, 2019, the FDA approved upadacitinib (Rinvoq), an…
Risankizumab & Apremilast Come to Market in Canada
In Canada, five provinces will now reimburse patients with plaque psoriasis who use risankizumab. Also, Canada Health has approved apremilast for treating adults with plaque psoriasis and psoriatic arthritis…
Sports Doctors May Accidentally Prescribe Banned Steroids
(Reuters Health)—Sports physicians routinely prescribe corticosteroids to athletes for conditions, such as inflammation, asthma and allergies, but not all of them know which forms of these drugs are banned under anti-doping rules, a study suggests. The survey of 603 physicians from 30 countries found four in five prescribe oral corticosteroids to athletes, one of the…
China Approves Use of Tocilizumab for Coronavirus Patients
BEIJING (Reuters)—China will use a Roche Holding AG arthritis drug to treat some coronavirus patients in severe conditions, health authorities said on Wednesday, as the country seeks to build up treatment regimens to help the infected recover. Tocilizumab, sold by the Swiss pharma giant under the trade name Actemra, can be prescribed to coronavirus patients…
Phase 3 Results for Olokizumab in RA Patients
In a recent study, olokizumab proved safe and effective for treating the signs and symptoms of RA and improving patients’ physical function…
Increasing Opioid Dose May Not Help Chronic Pain
NEW YORK (Reuters Health)—In patients with chronic musculoskeletal pain, an increase in opioid dosage appears to be of no clear benefit, according to a two-year study. As Benjamin J. Morasco, PhD, tells Reuters Health by email, “When we followed patients with chronic pain, who were already prescribed long-term opioid therapy, we found patients as a…
Low-Dose Methotrexate Can Cause Adverse Effects
NEW YORK (Reuters Health)—Low-dose methotrexate can be associated with gastrointestinal, pulmonary, infectious, hematologic and other adverse effects, according to an analysis of the Cardiovascular Inflammation Reduction Trial (CIRT). “Methotrexate is not a benign drug, even at dosages used for rheumatic diseases,” Daniel H. Solomon, MD, MPH of Brigham and Women’s Hospital, Boston, tells Reuters Health…
FDA Advisory Committees Reject Oxycodegol (NKTR-181) Application
FDA advisory committees rejected the new drug application for oxycodegol, an opioid analgesic, due to a lack of data regarding it’s potential for abuse…
Cannabinoids Show Potential in Pain Management
ATLANTA—The potential of cannabis‐based medicines is a hot topic, particularly as pain management therapy for arthritis and other conditions. However, confusion abounds regarding its therapeutic potential, how it can be administered and even the correct terminology to use. David P. Finn, PhD, professor of pharmacology and therapeutics, and founding co-director of the Centre for Pain…
- « Previous Page
- 1
- …
- 28
- 29
- 30
- 31
- 32
- …
- 120
- Next Page »